6505--Emtricitabine/Tenofovir Disoproxil Fumarate Tablets
ID: 36E79725R0035Type: Presolicitation
AwardedJun 27, 2025
$10M$9,977,968
AwardeeAVKARE LLC PULASKI 38478
Award #:36E79725D0046
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/17a9e124e0384359aebac1cc0302787d/view
Timeline
    Description

    The Department of Veterans Affairs is seeking proposals for the procurement of Emtricitabine 200mg/Tenofovir Disoproxil Fumarate 300mg tablets, a pharmaceutical product essential for healthcare services provided to veterans. The acquisition is unrestricted and requires compliance with federal regulations, including the Drug Supply Chain Security Act (DSCSA), with proposals needing to include pricing for the base year and four option years, as well as unique National Drug Codes (NDC) for each medication. This procurement aims to establish a reliable drug sourcing and distribution network to ensure consistent availability and pricing for governmental healthcare facilities, including the Department of Defense and the Indian Health Service. Interested parties should contact Contract Specialist Deborah S Fassl at Deborah.Fassl@va.gov for further details and submission requirements.

    Point(s) of Contact
    Deb FasslContract Specialist
    (708) 786-5894
    Deborah.Fassl@va.gov
    Files
    Title
    Posted
    36E79725R0035_1.docx
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for Emtricitabine 200mg/Tenofovir Disoproxil Fumarate 300mg Tablets, which will serve the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The solicitation number is 36E79725R0035, with a response deadline of May 13, 2025. The contract will provide an uninterrupted supply of the medication for a year, with options for four additional one-year terms. Offerors must ensure their product has a unique National Drug Code (NDC) and that proper packaging, including safety caps, is provided. The solicitation will be issued electronically on or around April 26, 2025, and all prospective bidders must regularly check SAM.gov for updates, as no paper copies will be available. The estimated annual usage is 91,583 bottles of the specified tablets. The contact for inquiries is Deb Fassl, whose email is provided. This procurement underscores the VA's commitment to maintaining pharmaceutical supplies for critical health programs.
    36E79725R0035.docx
    This document outlines a Request for Proposal (RFP) from the Department of Veterans Affairs for pharmaceutical products, specifically Emtricitabine 200mg/Tenofovir Disoproxil Fumarate 300mg tablets. The acquisition is unrestricted, with a focus on compliance with various federal regulations, including the Drug Supply Chain Security Act (DSCSA). Proposals must include pricing for the base year and four option years, and contain unique National Drug Codes (NDC) for each medication. The awarded contractor will establish a business relationship with Pharmaceutical Prime Vendor (PPV) programs, supplying drugs to various government participants, including the Department of Defense and the Indian Health Service. The document provides details on submission requirements, including the necessity of a manufacturer's Letter of Commitment if the offeror is not the manufacturer. Additionally, it stipulates packaging requirements, barcoding standards, and the conditions under which sales reports and Cost Recovery Fees must be submitted quarterly. The overall goal is to set up a reliable drug sourcing and distribution network to ensure consistent availability and pricing for governmental healthcare facilities.
    Similar Opportunities
    6505--36C77026Q0061/RFI/Domestic Sources Rx_MedSurge
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is seeking information from domestic pharmaceutical manufacturers through a Request for Information (RFI) designated 36C77026Q0061, aimed at supporting the Consolidated Mail Outpatient Pharmacy (CMOP) in fulfilling its Open Market (OM) purchasing needs. The RFI seeks to identify both small and large businesses capable of providing a range of pharmaceutical products and ancillary items, with a focus on those manufactured in the United States, to enhance the supply chain for approximately 450,000 prescriptions mailed daily to Veterans. Interested manufacturers are required to submit detailed company and product information, including FDA-approved NDC numbers and operational capabilities, by March 15, 2026, at 4:30 PM CT. For further inquiries, respondents can contact Michael McAlhaney at Michael.McAlhaney@va.gov or (913) 684-1976.
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    6505--Ustekinumab Pens/Syringes or Biosimilar
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Ustekinumab Pens/Syringes or Biosimilars, aimed at supplying various federal health entities including the Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will be awarded for an initial period of one year, with the possibility of four additional one-year option periods, ensuring a consistent supply of these critical pharmaceutical products through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique National Drug Code (NDC) numbers and ensure that any biosimilar products meet FDA licensing requirements, as outlined in the FDA Purple Book. The solicitation is expected to be released around January 12, 2026, with a tentative closing date of January 27, 2026; interested parties should direct inquiries to Chris Carthron at Christopher.Carthron@va.gov or (708) 786-4980.
    COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM - 762 TUCSON
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is conducting a Sources Sought Notice to identify potential qualified domestic sources for the procurement of COLESTIPOL HCL 1GM TAB and DESONIDE 0.05% CREAM through its National CMOP Office. This announcement serves as a market research tool rather than a solicitation, aiming to gather information on vendors' capabilities to meet the requirements outlined in the Statement of Requirements. The products sought are critical for pharmaceutical preparation and will support the healthcare needs of veterans. Interested vendors must submit their responses, including company details and capability statements, via email to Jennifer Coleman at Jennifer.Coleman4@va.gov by December 19, 2025, at 3:00 PM CDT. This notice does not obligate the VA to issue a solicitation.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for Trazodone HCL tablets in various dosages and bottle counts. This procurement aims to fulfill substantial pharmaceutical supply needs, emphasizing compliance with technical and quality requirements as outlined in the solicitation documents. The solicitation, identified as SPE2D2-26-R-0003, mandates electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Military Treatment Facilities (MTFs) and TRICARE pharmacies. This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs, which will be evaluated by the Pharmacy and Therapeutics (P&T) Committee. Key drugs under consideration include newly approved agents for lung cancer, antihypertensive agents, oncological agents, diuretics, antilipidemics, and targeted immunomodulatory biologics, with quotes due by January 5, 2026, for a committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Tracy Banks or Julia Trang via email for further details and ensure compliance with submission requirements outlined in the RFQ document HT9402-26-Q-9103.
    6505--Nicotine Lozenges MINI (VA-26-00020754)
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Nicotine Mini Lozenges, specifically under solicitation number 36E79726R0007. This contract aims to ensure an uninterrupted supply of nicotine lozenges for the VA, Department of Defense (DOD), Bureau of Prisons (BOP), and Indian Health Service (IHS), with a contract duration of one year and four optional one-year extensions. The estimated annual requirements include 166,791 bottles of 2mg lozenges and 138,276 bottles of 4mg lozenges, which will be distributed through the VA and DOD Pharmaceutical Prime Vendor Programs. Interested offerors should note that the solicitation will be electronically issued around December 18, 2025, with a tentative closing date of January 1, 2026, and can direct inquiries to Billy Fong at billy.fong@va.gov or by phone at 708-786-4992.